NEW PERSPECTIVES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - IPRIFLAVONE

被引：10
|
作者：
MOSCARINI, M [1 ]
PATACCHIOLA, F [1 ]
SPACCA, G [1 ]
PALERMO, P [1 ]
CASERTA, D [1 ]
VALENTI, M [1 ]
机构：
[1] UNIV LAQUILA,DEPT SURG,DIV OBSTET & GYNECOL,I-67100 LAQUILA,ITALY
来源：
GYNECOLOGICAL ENDOCRINOLOGY | 1994年 / 8卷 / 03期
关键词：
IPRIFLAVONE; OSTEOPOROSIS;
D O I：
10.3109/09513599409072456
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The efficacy and safety of ipriflavone, a new anti-osteoporotic agent, has been evaluated in an open study in 100 osteoporotic women. Ipriflavone was administered as oral capsules dosed at 200 mg, 3 times a day for 12 months. Ninety women completed the study, and the results indicate that the bone mineral density was increased by 2% and 5.8% after 6 and 12 months, respectively. Pain and rachis mobility seemed to be positively influenced by ipriflavone. Only three women complained of side-effects (gastralgia and nausea) and asked to stop the therapy.
引用
收藏
页码：203 / 207
页数：5
相关论文
共 50 条
  • [1] EFFICACY OF IPRIFLAVONE IN THE PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
    KOVACS, AB
    [J]. AGENTS AND ACTIONS, 1994, 41 (1-2): : 86 - 87
  • [2] Ipriflavone in the treatment of postmenopausal osteoporosis - A randomized controlled trial
    Alexandersen, P
    Toussaint, A
    Christiansen, C
    Devogelaer, JP
    Roux, C
    Fechtenbaum, J
    Gennari, C
    Reginster, JY
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (11): : 1482 - 1488
  • [3] Effects of ipriflavone on postmenopausal syndrome and osteoporosis
    Zhang, Xin
    Li, Shao-Wen
    Wu, Jin-Fang
    Dong, Chun-Li
    Zheng, Cai-Xia
    Zhang, Yun-Ping
    Du, Juan
    [J]. GYNECOLOGICAL ENDOCRINOLOGY, 2010, 26 (02) : 76 - 80
  • [4] Ipriflavone for the treatment of osteoporosis
    Y. K. Choi
    I. K. Han
    H. K. Yoon
    [J]. Osteoporosis International, 1997, 7 : 174 - 178
  • [5] Ipriflavone for the treatment of osteoporosis
    Choi, YK
    Han, IK
    Yoon, HK
    [J]. OSTEOPOROSIS INTERNATIONAL, 1997, 7 (Suppl 3) : 174 - 178
  • [6] IPRIFLAVONE - PHARMACOLOGICAL PROPERTIES AND USEFULNESS IN POSTMENOPAUSAL OSTEOPOROSIS
    REGINSTER, JYL
    [J]. BONE AND MINERAL, 1993, 23 (03): : 223 - 232
  • [7] Revisiting Ipriflavone: a Potential Isoflavone for the Management of Postmenopausal Osteoporosis
    Anish John
    Anoop Narayanan V
    Kiran Konkodi
    [J]. Revista Brasileira de Farmacognosia, 2021, 31 : 733 - 740
  • [8] Revisiting Ipriflavone: a Potential Isoflavone for the Management of Postmenopausal Osteoporosis
    John, Anish
    Narayanan, Anoop
    Konkodi, Kiran
    [J]. REVISTA BRASILEIRA DE FARMACOGNOSIA-BRAZILIAN JOURNAL OF PHARMACOGNOSY, 2021, 31 (06): : 733 - 740
  • [9] Ipriflavone and osteoporosis
    Schelonka, EP
    Usher, A
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (15): : 1836 - 1836
  • [10] NEW WAY TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
    Strukov, V. I.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2014, 25 : S213 - S214
12345